Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

Stock Information for Vaxart Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vaxart Inc.

Vaxart to Participate in BTIG Biotechnology Conference 2026
Vaxart Announces Results of Annual Meeting of Stockholders
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Vaxart Publishes Presentation Urging Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
Vaxart to Participate in BTIG Infectious Disease Day 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.